An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2022
Affiliation
Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.; Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.; Ivy Center for Family Wellness, The Society of St Vincent de Paul, Phoenix, Arizona.; Southwest Interdisciplinary Research Center, Arizona State University, Phoenix.; Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.; School of Public Health, University of Washington, Seattle.; Valley of the Sun YMCA, Phoenix, Arizona.; Ivy Center for Family Wellness, The Society of St Vincent de Paul, Phoenix, Arizona.; National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.; Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.
Authors
Peña Armando, Olson Micah L, Hooker Elva, Ayers Stephanie L, Castro Felipe González, Patrick Donald L, Corral Libby, Lish Elvia, Knowler William C, Shaibi Gabriel Q
Studies

Abstract

ImportanceLatino youths are disproportionately impacted by prediabetes and type 2 diabetes (T2D). Lifestyle intervention is the first-line approach for preventing or delaying T2D among adults with prediabetes.ObjectiveTo assess the efficacy of a diabetes prevention program among Latino youths aged 12 to 16 years with prediabetes.Design, setting, and participantsThis 2-group parallel randomized clinical trial with 2:1 randomization assessed a lifestyle intervention against usual care among Latino youths with prediabetes and obesity with 6- and 12-month follow-up. The study was conducted at YMCA facilities in Phoenix, Arizona from May 2016 to March 2020.InterventionParticipants were randomized to lifestyle intervention (INT) or usual care control (UCC). The 6-month INT included 1 d/wk of nutrition and health education and 3 d/wk of physical activity. UCC included 2 visits with a pediatric endocrinologist and a bilingual, bicultural registered dietitian to discuss diabetes risks and healthy lifestyle changes.Main outcomes and measuresInsulin sensitivity, glucose tolerance, and weight-specific quality of life (YQOL-W) at 6- and 12-month follow-up.ResultsA total of 117 Latino youths (mean [SD] age, 14 [1] years; 47 [40.1%] girls) were included in the analysis. Overall, 79 were randomized to INT and 38 to UCC. At 6 months, the INT led to significant decreases in mean (SE) 2-hour glucose (baseline: 144 [3] mg/dL; 6 months: 132 [3] mg/dL; P = .002) and increases in mean (SE) insulin sensitivity (baseline: 1.9 [0.2]; 6 months: 2.6 [0.3]; P = .001) and YQOL-W (baseline: 75 [2]; 6 months: 80 [2]; P = .006), but these changes were not significantly different from UCC (2-hour glucose: mean difference, -7.2 mg/dL; 95% CI, -19.7 to 5.3 mg/dL; P for interaction = .26; insulin sensitivity: mean difference, 0.1; 95% CI, -0.7 to 0.9; P for interaction = .79; YQOL-W: mean difference, 6.3; 95% CI, -1.1 to 13.7; P for interaction = .10, respectively). Both INT (mean [SE], -15 mg/dL [4.9]; P = .002) and UCC (mean [SE], -15 mg/dL [5.4]; P = .005) had significant 12-month reductions in 2-hour glucose that did not differ significantly from each other (mean difference, -0.3; 95% CI, -14.5 to 14.1 mg/dL; P for interaction = .97). At 12 months, changes in mean (SE) insulin sensitivity in INT (baseline: 1.9 [0.2]; 12 months: 2.3 [0.2]; P = .06) and UCC (baseline: 1.9 [0.3]; 12 months: 2.0 [0.2]; P = .70) were not significantly different (mean difference, 0.3; 95% CI, -0.4 to 1.0; P for interaction = .37). At 12 months, YQOL-W was significantly increased in INT (basline: 75 [2]; 12 months: 82 [2]; P Conclusions and relevanceIn this randomized clinical trial, both INT and UCC led to similar changes in T2D risk factors among Latino youths with diabetes; however, YQOL-W was improved in INT compared with UCC. Diabetes prevention interventions that are effective in adults also appeared to be effective in high risk youths.Trial registrationClinicalTrials.gov Identifier: NCT02615353.